5.8 C
New York
Monday, November 16, 2026

Zika vaccine nears first human trials in India

Must read

Trends News Stories Editorial
Trends News Stories Editorialhttps://trendsnewsstories.com/
Editorial desk at Trends News Stories (trendsnewsstories.com), an independent news site based in New Delhi, India. We publish original trending-news explainers across entertainment, sports, tech, business and health. Facts are checked against official sources and trusted outlets; we credit sources, note what is unconfirmed, and correct errors when we find them.

India’s first Zika vaccine moved closer to human trials after an expert panel of the Central Drugs Standard Control Organisation reviewed its Phase I trial protocol. Business Standard reported on 15 November 2026 that the vaccine was nearing human trials after the panel review, and the committee minutes show the panel took up the proposal at its meeting on 23 September 2026.

The vaccine is a recombinant live attenuated Zika vaccine in freeze-dried form. It is being developed by the Human Biologicals Institute, a division of government-affiliated drugmaker Indian Immunologicals Limited, together with Griffith University in Queensland, Australia. The Zika vaccine is the first of its kind in India, and the trial would be the first time it is tested in people.

The Zika virus spreads mainly through mosquito bites. There is no licensed vaccine to prevent Zika, and India has reported cases from several states. The health ministry recorded 537 Zika cases in India as of 22 July 2024.

Zika vaccine protocol reviewed in September

The CDSCO Subject Expert Committee on vaccines reviewed the Phase I protocol at its meeting on 23 September 2026, held in hybrid mode. The protocol is titled “A First-in-human, randomized, double-blind, placebo-controlled, Phase I study to evaluate the safety, reactogenicity, and immunogenicity of a recombinant Live attenuated Zika Vaccine (Freeze Dried) of Human Biologicals Institute, in healthy adult volunteers aged 18 to 50 years.”

The committee noted that the firm had completed acute dose and repeat dose toxicity studies, along with animal immunogenicity studies and animal challenge studies carried out by the Human Biologicals Institute, Indian Immunologicals and Griffith University.

The committee also noted gaps in the application. The firm had not submitted a scientific reason for the dose chosen for the Phase I study, had submitted only a summary report of its non-clinical studies, and had not given a statistical justification for the sample size, the 3:1 randomisation or the choice of cohorts. The committee recommended that the firm submit that information for further deliberation.

What the Phase I trial would test

A Phase I trial tests a vaccine in a small group of healthy volunteers for the first time in people. The Zika vaccine trial would test safety, reactogenicity and immunogenicity, which is the ability of the vaccine to prompt an immune response. The trial would enrol healthy adults aged 18 to 50, and the design is randomised, double-blind and placebo-controlled, so neither the volunteers nor the researchers know who receives the vaccine and who receives a placebo.

The vaccine is a codon de-optimized live-attenuated vaccine, a design that weakens the virus so it can train the immune system without causing disease. The vaccine has completed extensive pre-clinical evaluations, and the company has received permission to produce GMP-grade material for clinical development work.

Indian Immunologicals signed a memorandum of agreement with the Indian Council of Medical Research in September 2024 to advance the clinical development of the vaccine. Under the agreement, the ICMR will fund the Phase I trial costs, including the conduct, investigations and monitoring of the trial.

Zika vaccine work began with an ICMR pact

The Phase I trials will run at the ICMR network sites in India. The network has four sites: ACTREC in Mumbai, KEM Hospital in Mumbai, SRM in Chennai and PGIMER in Chandigarh. The network was set up to run first-in-human safety studies in India so Indian developers do not need to go abroad for early trials.

ICMR director general Dr Rajiv Bahl called the agreement a step towards Atmanirbhar Bharat and Viksit Bharat when it was signed. The agreement covers the clinical development of what would be India’s first Zika vaccine, and the ICMR funding covers the full cost of the Phase I trial.

The committee minutes record the Zika vaccine as jointly developed by Griffith University, the State of Queensland, Australia, and the Human Biologicals Institute. The panel has asked the company to submit the missing information, including the dose rationale and the full non-clinical study reports, before it deliberates further.

More articles

Latest article